Survey and Research Archives | Page 9 of 98 | Be Korea-savvy

Archive by category Survey and Research

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an involuntary movement disorder that develops in around 15%-25% of patients taking antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder2,3 Data presented at the European [...]

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS) New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-‘749 [...]

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions for patients and HCPs New data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified New ADVANCE survey findings highlight key patient-reported [...]

CertiK Engineer Recognized for Identifying Vulnerability in Apple Vision Pro’s Eye-Tracking Technology

CertiK Engineer Recognized for Identifying Vulnerability in Apple Vision Pro’s Eye-Tracking Technology

NEW YORK, Sept. 20, 2024 (Korea Bizwire) – CertiK, the industry-leading Web3 security firm, is proud to announce that Haoqi Shan, a distinguished member of CertiK’s engineering team, has been recognized for his critical role in identifying a vulnerability in Apple’s Vision Pro mixed reality headset. The findings, conducted in collaboration with five other computer [...]

Bitget Celebrates Its 6th Anniversary, Surpassing 45 Million Users

Bitget Celebrates Its 6th Anniversary, Surpassing 45 Million Users

VICTORIA, Seychelles, Sept. 20, 2024 (Korea Bizwire) – Bitget, the leading cryptocurrency exchange and Web3 company, proudly celebrates its 6th anniversary with a significant milestone — surpassing 45 million users worldwide, overtaking its competitors becoming the fourth largest crypto exchange by trading volume. The platform boasts as the fastest growing exchange with 400% user growth since [...]

New third-party analyses support General Fusion’s MTF technology path to commercialization

New third-party analyses support General Fusion’s MTF technology path to commercialization

SRNL and UKAEA, labs renowned for neutronics simulation, tritium innovation, and fuel cycle R&D, recently reviewed key parameters of the company’s unique approach to practical fusion energy RICHMOND, British Columbia, Sept. 19, 2024 (Korea Bizwire) – New analyses from the U.S. Savannah River National Laboratory (SRNL) and UK Atomic Energy Authority (UKAEA) support General Fusion’s [...]

Helping Ukraine Preserve Cultural Heritage through the ARK Project

Helping Ukraine Preserve Cultural Heritage through the ARK Project

LVIV, Ukraine, Sept. 19, 2024 (Korea Bizwire) – The Karel Komárek Family Foundation (KKFF), a leading Czech charity, in partnership with the “Supporting Ukrainian Culture” initiative, a joint project of the Ministry of Culture of the Czech Republic and the Czech Committee of International Council of Museums (ICOM) took further steps to help to preserve Ukrainian [...]

Carbon removal projects need to ramp up massively to meet future needs

Carbon removal projects need to ramp up massively to meet future needs

LONDON, September 19 2024 – Carbon removals, the removal and durable storage of carbon dioxide (CO2) that has already been emitted, are starting to emerge as a viable investment opportunity, but not at a pace that will enable the world to get to net zero according to the latest research by data and analytics company Wood Mackenzie.   The [...]

Global Virus Network’s Annual Meeting Fortifies Bonds on the African Continent to Catalyze Innovative Research, Strengthen Pandemic Preparedness, and Combat Scientific Misinformation

Global Virus Network’s Annual Meeting Fortifies Bonds on the African Continent to Catalyze Innovative Research, Strengthen Pandemic Preparedness, and Combat Scientific Misinformation

Duke-NUS Medical School’s Dr. Linfa Wang Awarded GVN’s 2024 Robert C. Gallo Award for Scientific Excellence and Leadership DURBAN, South Africa, Sept. 18, 2024 (Korea Bizwire) – The Global Virus Network concluded its annual meeting of closed scientific sessions held 16-18 September 2024 with a press conference. Co-hosted by the Centre for the AIDS Programme of Research in South Africa [...]

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging

SPRING, Texas, Sept. 18, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration with its clinical stage experimental therapeutic RXR agonist compound IRX4204. The presentation titled “The highly potent and selective third generation RXR nuclear receptor agonist compound IRX4204 has potential [...]